Genomics company Twist Bioscience has entered an antibody discovery, option and licence agreement with German drug manufacturer Bayer.

Twist Bioscience’s division Twist Biopharma Solutions will use its Library of Libraries to carry out antibody discovery campaigns against targets provided by Bayer.

Twist will receive payments linked to research initiation and is also eligible to receive fees linked to milestones in research and in the exercise of licensing options.

Success-based clinical and commercial milestone payments will also be provided for antibody leads discovered under the partnership that enter clinical development. Royalties will be offered on product sales.

Twist will be eligible for $188m in clinical and commercial milestone payments and royalties, while Bayer will have exclusive rights to license the antibodies for commercialisation in territories worldwide.

Twist Bioscience CEO and co-founder Emily Leproust stated: “Our ongoing partnership with Bayer leverages the full suite of our Twist Biopharma Solutions offering of antibody discovery services to identify the best antibodies for Bayer’s specific targets.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“By combining the scientific and technical strengths of each organisation, and importantly the level of mutual trust built over several years working together, we look forward to identifying and developing new therapies in multiple disease areas to positively impact patients who need it the most.”

This is the third collaboration between the two companies. In April 2023, Twist Bioscience collaborated to help Astellas Pharma discover antibodies for immunotherapies.